These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 29360414)

  • 1. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
    Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A
    J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
    Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
    J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
    Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
    Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
    Vijenthira A; Chan K; Cheung MC; Prica A
    Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.
    Stephens DM; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; LaCasce AS; Barr PM; Knopp MV; Hsi ED; Leonard JP; Kahl BS; Smith SM; Friedberg JW
    Blood; 2019 Oct; 134(15):1238-1246. PubMed ID: 31331918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
    Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
    Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
    André MPE; Girinsky T; Federico M; Reman O; Fortpied C; Gotti M; Casasnovas O; Brice P; van der Maazen R; Re A; Edeline V; Fermé C; van Imhoff G; Merli F; Bouabdallah R; Sebban C; Specht L; Stamatoullas A; Delarue R; Fiaccadori V; Bellei M; Raveloarivahy T; Versari A; Hutchings M; Meignan M; Raemaekers J
    J Clin Oncol; 2017 Jun; 35(16):1786-1794. PubMed ID: 28291393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.
    Bauer K; Skoetz N; Monsef I; Engert A; Brillant C
    Cochrane Database Syst Rev; 2011 Aug; (8):CD007941. PubMed ID: 21833963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma.
    Ganesan P; Rajendranath R; Kannan K; Radhakrishnan V; Ganesan TS; Udupa K; Lakshmipathy KM; Mahajan V; Sundersingh S; Rajaraman S; Krishnakumar R; Sagar TG
    Ann Oncol; 2015 Jun; 26(6):1170-1174. PubMed ID: 25701453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
    Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
    J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
    Straus DJ; Jung SH; Pitcher B; Kostakoglu L; Grecula JC; Hsi ED; Schöder H; Popplewell LL; Chang JE; Moskowitz CH; Wagner-Johnston N; Leonard JP; Friedberg JW; Kahl BS; Cheson BD; Bartlett NL
    Blood; 2018 Sep; 132(10):1013-1021. PubMed ID: 30049811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial.
    Russell J; Collins A; Fowler A; Karanth M; Saha C; Docherty S; Padayatty J; Maw K; Lentell I; Cooke L; Hodson A; Shah N; Sadullah S; Grigoropoulos N; Qian W; Kirkwood AA; Uttenthal BJ; Johnson P; Follows GA
    Ann Hematol; 2021 Apr; 100(4):1049-1058. PubMed ID: 33641019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
    J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
    Casasnovas RO; Bouabdallah R; Brice P; Lazarovici J; Ghesquieres H; Stamatoullas A; Dupuis J; Gac AC; Gastinne T; Joly B; Bouabdallah K; Nicolas-Virelizier E; Feugier P; Morschhauser F; Sibon D; Bonnet C; Berriolo-Riedinger A; Edeline V; Parrens M; Damotte D; Coso D; André M; Meignan M; Rossi C
    J Clin Oncol; 2022 Apr; 40(10):1091-1101. PubMed ID: 34990281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
    Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
    Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
    J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
    J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
    Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
    N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.